Alvotech is a biotechnology company dedicated to developing and manufacturing biosimilar medicines. Founded by Robert Wessman, it targets lower-cost alternatives to major biologic therapies using an integrated approach that covers research, regulatory work, and large-scale production.
The company currently markets five approved biosimilars in various regions, covering reference products such as Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva. Its pipeline spans autoimmune conditions, eye disorders, osteoporosis, respiratory issues, and oncology. Distribution relies on partners including TEVA, Sandoz, and Dr. Reddy's Laboratories to serve the United States, Europe, Japan, and additional markets.
In the past 30 days, ALVO has moved up approximately 20%, advancing from a late-August close near $4.91 to around $5.89. The gains have come in sharp, event-driven bursts rather than a gradual climb, highlighted by a 7.9% jump in a single mid-September session.
Looking back over the quarter, the picture strengthens further. Three months prior the shares closed near $3.48, translating to roughly 69% appreciation. This recovery stands out after the stock traded under pressure for much of the first half of 2026, hovering close to its 52-week low of $2.94 amid manufacturing and approval concerns.
Multiple concrete developments fueled the latest advance. Barclays issued a double upgrade in mid-September, with analyst Glen Santangelo moving the rating to Overweight from Underweight and lifting the price target to $8 from $4, based on expectations for three FDA approvals later this year. The stock rose 7.9% on that news, its largest one-day gain in months.
Bank of America started coverage with a Buy rating and $7 target, describing the company as nearing an inflection point where focus shifts from regulatory questions to commercial execution. The FDA also accepted the Biologics License Application for AVT80, a proposed biosimilar to Entyvio in prefilled syringe and pen formats. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The broader quarterly move reflects resolution of the main issues that weighed on the shares earlier in 2026: manufacturing compliance and U.S. approval timelines. In July the FDA closed its inspection of the Reykjavik facility with a Voluntary Action Indicated classification, removing a key hurdle.
Around the same period the company resubmitted applications for AVT05 (biosimilar to JNJ Simponi), AVT06 (biosimilar to REGN Eylea), and AVT03 (biosimilar to AMGN Prolia/Xgeva). Leadership transitioned with Lisa Graver becoming CEO in late March 2026, and the balance sheet was bolstered by about $165 million in equity proceeds plus a $75 million term loan. Although first-half revenue declined year over year due to manufacturing slowdowns, management stood by its full-year outlook, helping stabilize sentiment.
The main upcoming driver remains the FDA review of the Simponi, Eylea, and Prolia/Xgeva biosimilar applications, with decisions expected on or before December 4, 2026. Approval timing along with any intellectual-property outcomes will influence U.S. launch plans.
Attention will also turn to third-quarter results and commentary on manufacturing progress, as the fourth quarter is expected to be the strongest period once supply normalizes. Other areas include advancement on the Entyvio program, the high-dose Eylea candidate, and the FUJIFILM Biotechnologies partnership slated to add U.S. capacity from late 2027 onward. From what I see, pricing and reimbursement trends in the biosimilar space continue to warrant close attention.
In my view, combining fundamental analysis with algorithmic signals can add useful perspective when following names like this one. Tickeron’s AI Trend Prediction Engine has been a tool I turn to occasionally for an additional data layer on price behavior and pattern recognition across a wide range of equities.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALVO declined for three days, in 233 of 294 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALVO as a result. In 69 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for ALVO turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 34 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for ALVO entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALVO's RSI Oscillator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ALVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.057) is normal, around the industry mean (6.379). P/E Ratio (-7.839) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric